Preferred Label : PI3K Alpha/Beta Inhibitor BAY1082439;
NCIt related terms : BAY-1082439;
NCIt definition : An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha
and beta isoforms with potential antineoplastic activity. PI3K alpha/beta inhibitor
BAY1082439 selectively inhibits both PI3K alpha, including mutated forms of PIK3CA,
and PI3K beta in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis
and growth inhibition in PI3K-expressing and/or PTEN-driven tumor cells. By specifically
targeting class I PI3K alpha and beta, this agent may be more efficacious and less
toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently
found in solid tumors and results in increased tumor cell growth, survival, and resistance
to chemotherapy and radiotherapy. PIK3CA, one of the most highly mutated oncogenes,
encodes the p110-alpha catalytic subunit of the class I PI3K. PTEN, a tumor suppressor
protein and negative regulator of PI3K activity, is often mutated in a variety of
cancer cells.;
UNII : 59784ZX4GD;
CAS number : 1375469-38-7;
Molecule name : BAY1082439;
NCI Metathesaurus CUI : CL438339;
Origin ID : C103861;
UMLS CUI : C3641660;
Semantic type(s)
- concept_is_in_subset
- has_target
